

Headlands Research and Sahara Behavioral Health Partner to Provide Positive Mental Health Outcomes for Patients

The collaboration improves access to clinical research and investigational treatments while supporting participant recruitment efforts in Arizona.

SAN FRANCISCO, CA, USA, January 4, 2024 /EINPresswire.com/ -- Headlands Research, a leading

"

Partnering with Sahara
Behavioral Health draws on
our extensive experience in
psychiatric trials and
emphasizes our
commitment to expanding
clinical trial access"

Kyle Burtnett, CEO of
Headlands Research

multinational network of clinical trial sites, today announced a partnership with Sahara Behavioral Health to improve the accessibility of clinical research and investigational therapies for those seeking psychiatric and addiction care in Arizona.

"Partnering with Sahara Behavioral Health draws on our extensive experience in psychiatric trials and emphasizes our commitment to expanding clinical trial access," said Kyle Burtnett, CEO of Headlands Research. "This relationship is a win for all involved — for sponsors looking to conduct research in Arizona, for providers searching for

more treatment options, and most importantly, for local people seeking positive mental health outcomes."

Headlands Research specializes in large-volume recruitment and retention of diverse, inclusive, and specialty populations while delivering the highest quality data. The network relies on expert clinical researchers and renowned key opinion leaders who prioritize the participant experience. Through community and physician partnerships, a broad range of therapeutic expertise, and a commitment to advancing innovative medical therapies, Headlands Research aims to make clinical research accessible to all individuals.

Sahara Behavioral Health offers a diverse range of services designed to treat children, adolescents, adults, and seniors with conditions such as depression, anxiety, substance abuse, ADHD, PTSD, and more. With several locations across Arizona, Sahara Behavioral Health prioritizes compassionate, accessible, and culturally inclusive care.

"At Sahara Behavioral Health, we are committed to our patients, profession, and community; commitments we believe align with the values and mission of Headlands Research," said Dr. Satinder Purewal, Medical Director of Psychiatry and Founder of Sahara Behavioral Health. "Together, our organizations create many opportunities for improved outcomes for patients seeking mental health and addiction treatment."

To learn more about Headlands
Research and its extensive network of research sites, visit
https://headlandsresearch.com,
contact info@headlandsresearch.com,
or follow the company on LinkedIn.



About Headlands Research

Headlands Research is a multinational integrated clinical trial site organization with a mission to improve lives by advancing innovative medical therapies. Its network of sites focuses on large-volume recruitment and retention of diverse, inclusive, and specialty populations while delivering the highest quality data. Headland Research's principal investigators and KOLs are proven experts in a broad range of therapeutic areas. To date, Headlands Research has successfully supported more than 5,000 clinical trials. For more information, visit www.headlandsresearch.com.

About Sahara Behavioral Health

At Sahara Behavioral Health, our mission is to improve lives by providing compassionate, effective mental health and addiction services to our community. Our treatment approaches are individualized to each patient's unique needs. We serve patients through all stages of life, including children, adolescents, adults, and seniors. We take pride in offering our patients the highest standard of care with a comprehensive approach that includes assessment and diagnosis, medication management, and treatment services. Sahara Behavioral Health offers inperson or tele-video appointments and has six locations across Arizona in Anthem, Chandler, Glendale, Peoria, Surprise, and Tucson. In addition to medication management, we provide inoffice treatments, including Esketamine, Ketamine, and transcranial magnetic stimulation (TMS).

Contact: Brittany Kearns Phone: 919-270-8054 Email: brittany@crossroadsb2b.com

© 1995-2024 Newsmatics Inc. All Right Reserved.

Brittany Kearns Crossroads B2B Consulting 9192708054 ext. brittany@crossroadsb2b.com

This press release can be viewed online at: https://www.einpresswire.com/article/678897515 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.